The Distribution of Plasma Drug Concentrations of Beta-lactam Antibiotics in Intensive Care Unit Patients
Completed
- Conditions
- Sepsis
- Registration Number
- NCT02446392
- Lead Sponsor
- Linkoeping University
- Brief Summary
In this project, intensive care unit (ICU) patients treated with beta-lactam antibiotics are included with the aim to investigate the potential underdosing in this patient group. Four regional ICU-clinics are recruiting consecutive patients (n=120) and samples are taken before the next dose is administered for three consecutive days.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Current treatment with beta-lactam antibiotics and admission to the ICU
Exclusion Criteria
- Pregnancy, age below 18 years
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of patients below 16mg/L for piperacillin-tazobactam, 2 mg/L for meropenem and 4mg/L for cefotaxim 3 days
- Secondary Outcome Measures
Name Time Method Mortality in relation to initial levels of beta-lactam antibiotics as defined in primary outcome 30 days The rate of patients below 100% time over MIC in relation to the bacteria causing the infection. 3 days Kidney function measured as eGFR in relation to initial levels of beta-lactam antibiotics as defined in primary outcome 3 days SAPS-score in relation to initial levels of beta-lactam antibiotics as defined in primary outcome 3 days Days in intensive care unit in relation to initial levels of beta-lactam antibiotics as defined in primary outcome 30 days
Trial Locations
- Locations (2)
Intensive care unit
🇸🇪Växjö, Sweden
Intensive Care Unit
🇸🇪Linköping, Sweden